MEDIA

Nomination Committee for the 2025 Annual General Meeting in Nanexa AB (publ)

14 February, 2025
- Regulatory
Download attachment

The Nomination Committee for the Annual General Meeting 2025 in Nanexa AB (publ) has been appointed.

The members of the Nomination Committee are:

  • Marlon Värnik, Exelity
  • Jonas Pålsson
  • Göran Ando, Chairman of the Board, adjunct

The Nomination Committee's proposals will be presented in the notice to the 2025 Annual General Meeting and on the company's website, www.nanexa.com.

Shareholders may contact the Nomination Committee with suggestions regarding its work by sending e-mail to info@nanexa.se (heading "Nanexa's Nomination Committee") or by letter to: Nanexa AB, Attn: Nanexa's Nomination Committee, Virdings Allé 2, SE-754 50, Uppsala, Sweden.

The Annual General Meeting will be held in Uppsala on 15 May 2025.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ) 
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com

The company’s Certified Adviser is Carnegie Investment Bank AB (publ).

About Nanexa AB (publ)

Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others Novo Nordisk and AstraZeneca.

Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments

Nomination Committee for the 2025 Annual General Meeting in Nanexa AB (publ)